在人类胰腺中发现增强剂-促进剂相互作用的全基因组发现,使用改进的基于活动-通过-接触的模型
Andreas W Schmidt1, German Demidov2, Ferdinand Krannich3
1Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany; Department of Internal Medicine I, Martin Luther University (MLU), Halle (Saale), Germany; Paediatric Nutritional Medicine, Else Kröner Fresenius Center for Nutritional Medicine (EKFZ), Technical University of Munich (TUM), Freising, Germany.
概括
我们开发了一种新的模型 (caABC) 来准确识别胰腺增强剂及其基因,改进了了解胰腺疾病中的基因调节的现有方法.
科学领域:
- 基因组学就是基因组学.
- 基因规则 基因规则
- 计算生物学 计算生物学
背景情况:
- 增强剂调节组织特异性基因表达,并携带与胰腺疾病相关的变异.
- 精确的增强剂-标基因分配至关重要,但具有挑战性.
- 现有的模型,如活动按接触 (ABC) 和通用ABC (gABC),在解释性方面存在局限性.
研究的目的:
- 在胰腺数据集中评估和改进增强剂向基因分配模型.
- 开发一种新的模型,平衡胰腺基因调节的性能和可解释性.
- 创建一个全面的全基因组数据集的胰腺增强剂和他们的基因.
主要方法:
- 将基底ABC和gABC模型应用于胰腺数据集,以进行增强剂-标基因映射.
- 开发了基于正典转录和适应的ABC (caABC) 模型,以提高可解释性.
- 使用胰腺表达量特征位置 (eQTLs) 进行了ABC,gABC和caABC性能比较,并评估了CTRC位置.
主要成果:
- 在胰腺中,gABC和caABC的表现明显优于基底ABC模型.
- caABC表现出与gABC可比的性能,具有增强的解释性.
- 在CTRC慢性胰腺炎风险位置,caABC成功区分了与疾病相关的变异.
结论:
- 该caABC模型为胰腺增强剂-点基因分配提供了一个强大的和可解释的方法.
- 我们生成了一个全基因组的胰腺特异性增强剂和基因的数据集.
- 该资源有助于优先考虑胰腺疾病中的调控突变.
相关概念视频
00:49What is Genetic Engineering?
Overview
01:09Recombinant DNA
Overview
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...